Leahy pushes for low-cost drugs

In time for the Toronto AIDS conference, U.S. Senator Patrick Leahy
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WASHINGTON—In time for the Toronto AIDS conference, U.S. Senator Patrick Leahy (D-Vt) pushed for action on legislation he introduced to facilitate production of low-cost versions of drugs for people in the world's poorest countries.
 
Under the Life-Saving Medicines Export Act (S.3175), U.S.-based generic drug companies would be allowed to manufacture generic versions of patented drugs for export to countries in need without permission of the patent holder, which would receive royalties.
 
"Our society too often acts as if we are powerless to do anything about the fact that the high price of many life-saving medicines—medicines that we take for granted—are beyond reach for millions of the world's most vulnerable people," Leahy says. "The need for these medicines is clear and present, but the market to provide them is not. The incentives in this bill would help change that."
 
Leahy's group argues that the act will not take business away from patent-holders as the medicines they manufacture are not currently being purchased by the low-income families found in needy countries. Furthermore, the generic products would be marked as "not for resale" in developed nations, and therefore would not undercut existing sales to these regions.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue